Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017433 · ClinicalTrials.gov registry record · Phase 2
Arsenic Trioxide in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by CTI BioPharma.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00017433: Clinical Trial Phase 2 study, sponsored by CTI BioPharma.
NCT00017433 is a Phase 2 study that was terminated before completion, run by CTI BioPharma. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017433, a Phase 2 study, was terminated before completion, sponsored by CTI BioPharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory stage II or stage III multiple myeloma.
Interventions
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-01 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Why NCT00017433 stopped before completion
NCT00017433 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which arsenic trioxide is the first listed.
NCT00017433 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00017433 about?
NCT00017433 is a clinical study titled "Arsenic Trioxide in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory stage II or stage III multiple myeloma.
What is the current status of trial NCT00017433?
This trial is currently terminated. It is a Phase 2 study. The study started on 2001-01. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00017433?
The interventions under investigation include: arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00017433?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia